Hemab Therapeutics Holdings, Inc. (COAG) competitors & alternatives
Health Care · NASDAQ
Hemab Therapeutics Holdings, Inc. (COAG)'s top competitors and alternatives — its most similar public companies — include CONTEXT THERAPEUTICS INC (CNTX), XENCOR INC (XNCR), Aardvark Therapeutics, Inc. (AARD), COMPASS THERAPEUTICS (CMPX), AVALYN PHARMA INC (AVLN), CRESCENT BIOPHARMA INC (CBIO), KODIAK SCIENCES INC (KOD), ANAPTYSBIO INC (ANAB), VOR BIOPHARMA INC (VOR), EVOMMUNE INC (EVMN), TENAX THERAPEUTICS INC (TENX) and RELAY THERAPEUTICS INC (RLAY). These are Hemab Therapeutics Holdings, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top COAG competitors & alternatives
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.61 (as of 2026-07-22) · market cap $56M
-
XENCOR INCXNCRHealth Care
Xencor is a clinical-stage biopharmaceutical company leveraging its proprietary XmAb antibody engineering platform to develop innovative multi-specific…
$19.51 (as of 2026-07-22) · market cap $1.4B
-
Aardvark Therapeutics, Inc.AARDHealth Care
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease…
$6.48 (as of 2026-07-22) · market cap $128M
-
COMPASS THERAPEUTICSCMPXHealth Care
Compass Therapeutics is a clinical-stage oncology company developing a pipeline of bispecific and agonistic antibodies designed to treat solid tumors by…
$2.04 (as of 2026-07-22) · market cap $367M
-
AVALYN PHARMA INCAVLNHealth Care
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled drug formulations for the treatment of rare respiratory diseases.
$28.72 (as of 2026-07-22) · market cap $1.3B
-
CRESCENT BIOPHARMA INCCBIOHealth Care
Crescent Biopharma is a clinical-stage oncology company developing a novel PD-1 x VEGF bispecific antibody and a portfolio of antibody-drug conjugates to…
$15.83 (as of 2026-07-22) · market cap $615M
-
KODIAK SCIENCES INCKODHealth Care
Kodiak Sciences is a pre-commercial retina biotech pioneering ultra-long-acting intravitreal biologics via its ABC platform, with lead anti-VEGF Zenkuda…
$41.92 (as of 2026-07-22) · market cap $2.6B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
Not quite? Describe exactly what you want →
Peers are Hemab Therapeutics Holdings, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Hemab Therapeutics Holdings, Inc. (COAG).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.